“海氏法则”如何帮助临床医生？ - Suppr

How can 'Hy's law' help the clinician?

作者信息

Senior John R

机构信息

Office of Pharmacoepidemiology and Statistical Science, Center for Drug Evaluation and Research, Food and Drug Administration HFD-030, Silver Spring, MD 20993, USA.

出版信息

Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):235-9. doi: 10.1002/pds.1210.

DOI:10.1002/pds.1210

PMID:16552792

Abstract

摘要

相似文献

How can 'Hy's law' help the clinician?

Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):235-9. doi: 10.1002/pds.1210.

Hy's law: predicting serious hepatotoxicity.

Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):241-3. doi: 10.1002/pds.1211.

'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective.

Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):221-9. doi: 10.1002/pds.1209.

Rules and laws of drug hepatotoxicity.

Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):231-3. doi: 10.1002/pds.1212.

Drug-induced hepatotoxicity.

N Engl J Med. 2003 Jul 31;349(5):474-85. doi: 10.1056/NEJMra021844.

Avoiding hepatic injury from drugs.

Gastroenterology. 1999 Oct;117(4):759. doi: 10.1016/s0016-5085(99)70329-x.

A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience.

Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):213-20. doi: 10.1002/pds.1207.

Serious liver injury. Leading reason for drug removals, restrictions.

FDA Consum. 2001 May-Jun;35(3):8-9.

Ximelagatran: an eulogy.

Thromb Res. 2006;118(3):301-4. doi: 10.1016/j.thromres.2006.02.012. Epub 2006 Apr 19.

Predicting potential liver toxicity from phase 2 data: a case study with ximelagatran.

Stat Med. 2014 Jul 30;33(17):2914-23. doi: 10.1002/sim.6142. Epub 2014 Mar 12.

引用本文的文献

Natural History of Idiosyncratic Drug-Induced Liver Injury and Prognostic Models.

Liver Int. 2025 Jun;45(6):e70138. doi: 10.1111/liv.70138.

Genome-wide association study of abnormal elevation of ALT in patients exposed to atabecestat.

BMC Genomics. 2023 Sep 1;24(1):513. doi: 10.1186/s12864-023-09625-6.

Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials?

Cardiol J. 2023;30(5):747-752. doi: 10.5603/CJ.a2021.0081. Epub 2021 Aug 6.

The Indian Network of Drug-Induced Liver Injury: Etiology, Clinical Features, Outcome and Prognostic Markers in 1288 Patients.

J Clin Exp Hepatol. 2021 May-Jun;11(3):288-298. doi: 10.1016/j.jceh.2020.11.002. Epub 2020 Nov 17.

Liraglutide-Induced Hepatotoxicity.

Biomedicines. 2021 Jan 22;9(2):106. doi: 10.3390/biomedicines9020106.

The Origins of the Modern-Day Study of Drug Hepatotoxicity: Focus on Hyman J. Zimmerman.

Clin Liver Dis (Hoboken). 2020 Mar 2;15(Suppl 1):S25-S36. doi: 10.1002/cld.856. eCollection 2020 Feb.

Drug-induced liver injury: Do we know everything?

World J Hepatol. 2017 Apr 8;9(10):491-502. doi: 10.4254/wjh.v9.i10.491.

Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.

Expert Rev Gastroenterol Hepatol. 2016;10(4):517-36. doi: 10.1586/17474124.2016.1127756. Epub 2015 Dec 25.

Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.

Drug Saf. 2012 Oct 1;35(10):865-75. doi: 10.1007/BF03261982.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

How can 'Hy's law' help the clinician?

Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):235-9. doi: 10.1002/pds.1210.

Hy's law: predicting serious hepatotoxicity.

Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):241-3. doi: 10.1002/pds.1211.

'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective.

Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):221-9. doi: 10.1002/pds.1209.

Rules and laws of drug hepatotoxicity.

Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):231-3. doi: 10.1002/pds.1212.

Drug-induced hepatotoxicity.

N Engl J Med. 2003 Jul 31;349(5):474-85. doi: 10.1056/NEJMra021844.

Avoiding hepatic injury from drugs.

Gastroenterology. 1999 Oct;117(4):759. doi: 10.1016/s0016-5085(99)70329-x.

A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience.

Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):213-20. doi: 10.1002/pds.1207.

Serious liver injury. Leading reason for drug removals, restrictions.

FDA Consum. 2001 May-Jun;35(3):8-9.

Ximelagatran: an eulogy.

Thromb Res. 2006;118(3):301-4. doi: 10.1016/j.thromres.2006.02.012. Epub 2006 Apr 19.

Predicting potential liver toxicity from phase 2 data: a case study with ximelagatran.

Stat Med. 2014 Jul 30;33(17):2914-23. doi: 10.1002/sim.6142. Epub 2014 Mar 12.

引用本文的文献

Natural History of Idiosyncratic Drug-Induced Liver Injury and Prognostic Models.

Liver Int. 2025 Jun;45(6):e70138. doi: 10.1111/liv.70138.

Genome-wide association study of abnormal elevation of ALT in patients exposed to atabecestat.

BMC Genomics. 2023 Sep 1;24(1):513. doi: 10.1186/s12864-023-09625-6.

Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials?

Cardiol J. 2023;30(5):747-752. doi: 10.5603/CJ.a2021.0081. Epub 2021 Aug 6.

The Indian Network of Drug-Induced Liver Injury: Etiology, Clinical Features, Outcome and Prognostic Markers in 1288 Patients.

J Clin Exp Hepatol. 2021 May-Jun;11(3):288-298. doi: 10.1016/j.jceh.2020.11.002. Epub 2020 Nov 17.

Liraglutide-Induced Hepatotoxicity.

Biomedicines. 2021 Jan 22;9(2):106. doi: 10.3390/biomedicines9020106.

The Origins of the Modern-Day Study of Drug Hepatotoxicity: Focus on Hyman J. Zimmerman.

Clin Liver Dis (Hoboken). 2020 Mar 2;15(Suppl 1):S25-S36. doi: 10.1002/cld.856. eCollection 2020 Feb.

Drug-induced liver injury: Do we know everything?

World J Hepatol. 2017 Apr 8;9(10):491-502. doi: 10.4254/wjh.v9.i10.491.

Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.

Expert Rev Gastroenterol Hepatol. 2016;10(4):517-36. doi: 10.1586/17474124.2016.1127756. Epub 2015 Dec 25.

Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.

Drug Saf. 2012 Oct 1;35(10):865-75. doi: 10.1007/BF03261982.

How can 'Hy's law' help the clinician?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献